FDA
-
-
-
-
-
-
-
TESARO (TSRO) Reports Updated Phase 1 GARNET Data of TSR-042 (anti-PD-1 antibody) in Patients with Recurrent or Advanced MSI-H
-
-
-
-
-
-
-
TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Pre-Open Movers 06/20: (CLBS) (CLPS) (WGO) Higher; (LZB) (ORCL) (SBUX) Lower (more...)
-
-
-
-
-
-
-
TESARO (TSRO) Says Quadra Trial of ZEJULA Achieved Primary Endpoint
-
-
-
-
-
-
-
Pre-Open Movers 03/27: (ATRS) (PETX) (RHT) Higher; (LFIN) (GERN) (OSTK) Lower (more...)
-
-
-
-
-
-
-
TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion
-
-
-
-
-
-
-
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

